{"pmid":32405269,"pmcid":"PMC7217787","title":"Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.","text":["Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.","Clin Immunol","Omarjee, Loukman","Janin, Anne","Perrot, Frederique","Laviolle, Bruno","Meilhac, Olivier","Mahe, Guillaume","32405269"],"journal":"Clin Immunol","authors":["Omarjee, Loukman","Janin, Anne","Perrot, Frederique","Laviolle, Bruno","Meilhac, Olivier","Mahe, Guillaume"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405269","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.clim.2020.108464","keywords":["cd, cluster of differentiation","covid-19, corona-virus-disease-2019","ctla-4, cytotoxic t lymphocyte associated protein 4","g-csf, granulocyte colony stimulating factor","ifn-gamma, interferon gamma","il, interleukin","ip-10, interferon gamma-induced protein 10","mcp-1, monocyte chemoattractant protein 1","mip-1alpha, macrophage inflammatory protein 1 alpha","nf-kappab, nuclear factor-kappa b","nlrp3, nucleotide-binding oligomerization domain (nod)-like receptor family, pyrin domain containing 3","pd-1, programmed cell death 1","ros, reactive oxygen species","sars-cov-2, severe acute respiratory syndrome coronavirus 2","tigit, t-cell immunoreceptor with ig and itim (immunoreceptor tyrosine-based inhibition motif) domains","tlr, toll like receptor","tnfalpha, tumor necrosis factor alpha","tim-3, t-cell immunoglobulin mucin-3","mtor, mammalian target of rapamycin"],"e_drugs":["Sirolimus"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845466230785,"score":9.490897,"similar":[{"pmid":32405226,"pmcid":"PMC7217791","title":"Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.","text":["Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.","Artemisinins are sesquiterpene lactones with a peroxide moiety that are isolated from the herb Artemisia annua. It has been used for centuries for the treatment of fever and chills, and has been recently approved for the treatment of malaria due to its endoperoxidase properties. Progressively, research has found that artemisinins displayed multiple pharmacological actions against inflammation, viral infections, and cell and tumour proliferation, making them effective against diseases. Moreover, it has displayed a relatively safe toxicity profile. The use of artemisinins against different respiratory diseases has been investigated in lung cancer models and inflammatory-driven respiratory disorders. These studies revealed the ability of artemisinins in attenuating proliferation, inflammation, invasion, and metastasis, and in inducing apoptosis. Artemisinins can regulate the expression of pro-inflammatory cytokines, nuclear factor-kappa B (NF-kappaB), matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), promote cell cycle arrest, drive reactive oxygen species (ROS) production and induce Bak or Bax-dependent or independent apoptosis. In this review, we aim to provide a comprehensive update of the current knowledge of the effects of artemisinins in relation to respiratory diseases to identify gaps that need to be filled in the course of repurposing artemisinins for the treatment of respiratory diseases. In addition, we postulate whether artemisinins can also be repurposed for the treatment of COVID-19 given its anti-viral and anti-inflammatory properties.","Pharmacol Res","Cheong, Dorothy H J","Daniel Tan, W S","Fred Wong, W S","Tran, Thai","32405226"],"abstract":["Artemisinins are sesquiterpene lactones with a peroxide moiety that are isolated from the herb Artemisia annua. It has been used for centuries for the treatment of fever and chills, and has been recently approved for the treatment of malaria due to its endoperoxidase properties. Progressively, research has found that artemisinins displayed multiple pharmacological actions against inflammation, viral infections, and cell and tumour proliferation, making them effective against diseases. Moreover, it has displayed a relatively safe toxicity profile. The use of artemisinins against different respiratory diseases has been investigated in lung cancer models and inflammatory-driven respiratory disorders. These studies revealed the ability of artemisinins in attenuating proliferation, inflammation, invasion, and metastasis, and in inducing apoptosis. Artemisinins can regulate the expression of pro-inflammatory cytokines, nuclear factor-kappa B (NF-kappaB), matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), promote cell cycle arrest, drive reactive oxygen species (ROS) production and induce Bak or Bax-dependent or independent apoptosis. In this review, we aim to provide a comprehensive update of the current knowledge of the effects of artemisinins in relation to respiratory diseases to identify gaps that need to be filled in the course of repurposing artemisinins for the treatment of respiratory diseases. In addition, we postulate whether artemisinins can also be repurposed for the treatment of COVID-19 given its anti-viral and anti-inflammatory properties."],"journal":"Pharmacol Res","authors":["Cheong, Dorothy H J","Daniel Tan, W S","Fred Wong, W S","Tran, Thai"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405226","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.phrs.2020.104901","keywords":["2dg, 2-deoxy-d-glucose","3-nt, 3-nitrotyrosine","4ebp1, eukaryotic translation initiation factor 4e-binding protein 1","8-ohdg, 8-hydroxy-2'-deoxyguanosine","8-iso, 8-isoprostane","abcg2, atp-binding cassette subfamily member 2","ace2, angiotensin-converting enzyme 2","aec, alveolar epithelial cells","ahr, airway hyperresponsiveness","aif, apoptosis-inducing factor","ali, acute lung injury","ap-1, activator protein 1","artd, artemisinin-daumone hybrid 15","asc, apoptosis-associated speck-like protein containing card","atf3, activating transcription factor 3","atp, adenosine triphosphate","arteether (pubchem cid: 3000469)","artemether (pubchem cid: 68911)","artemisitene (pubchem cid: 11000442)","artesunate (pubchem cid:156252)","axin2, axis inhibition protein 2","balf, bronchoalveolar lavage fluid","bdha, biotinylated dihydroartesunate","cddp, cisplatin","cdk, cyclin-dependent kinase","copd, chronic obstructive pulmonary disease","covid-19","cox-2, cyclooxygenase-2","cse, cigarette smoke extract","ctx, cyclophosphamide","chemical compounds studied in this article artemisinin (pubchem cid: 68827)","dha, dihydroartemisinin","dha-nlc, dihydroartemisinin-nanostructured lipid carriers","dlaedried, leaf artemisia extract","dna, deoxyribonucleic acid","dihydroartemisinin (pubchem cid: 139073990)","e2f1, e2f transcription factor 1","egfr, epidermal growth factor receptor","emt, epithelial-mesenchymal transition","er, endoplasmic reticulum","foxo1, forkhead box o1","glut, glucose transporter","gpx, glutathione peroxidase","gsh, glutathione","gsk3beta, glycogen synthase kinase 3 beta","h2ax, h2a histone family member x","hcmv, human cytomegalovirus","hdac2, histone deacetylase 2","helf, human embryonic lung fibroblasts","hif-1alpha, hypoxia-inducible factor 1-alpha","hnf4a, hepatocyte nuclear factor 4 alpha","ho-1, heme oxygenase-1","icam-1, intercellular adhesion molecule 1","il, interleukin","inf, interferon","ip-10, ifngamma-induced protein 10","ikappabalpha, inhibitor of nf-kappab alpha","jnk, c-jun n-terminal kinase","kc, keratinocyte chemoattractant","kdr/flk-1, kinase insert domain receptor /fetal liver kinase-1","keap1, kelch-like ech-associated protein 1","ladpi, liposomal artesunate dry powder inhalers","ld50, lethal dose","llc, lewis lung carcinoma","lmvd, lymphatic microvessel density","lps, lipopolysaccharide","lymp, lymphocyte","mapk, mitogen-activated protein kinases","mcp-1, monocyte chemoattractant protein-1","mda, malondialdehyde","mip-2, macrophage inflammatory protein 2","mmp, matrix metalloproteinase","mpo, myeloperoxidase","mac, macrophage","mcl-1, myeloid cell leukemia-1","nf-kappab, nuclear factor-kappa b","nkd2, naked cuticle homolog 2","nlrp3, nlr family pyrin domain containing 3","no, nitric oxide","nox, nadph oxidase","npc, nasopharyngeal carcinoma","nqo1, nad(p)h quinone dehydrogenase 1","nsclc, non-small cell lung cancer","nrf2, nuclear factor erythroid 2-related factor 2","ova, ovalbumin","pcna, proliferating cell nuclear antigen","peg, polyethylene glycol","pge2, prostaglandin e2","pi3k, phosphoinositide 3-kinase","ra, fls rheumatoid arthritis fibroblast-like synoviocytes","rankl, receptor activator of nuclear factor kappa-b ligand","rir, renal ischemia reperfusion","rnai, rna interference","ros, reactive oxygen species","rb, retinoblastoma","respiratory diseases","sclc, small cell lung cancer","sle, systemic lupus erythematosus","sod, superoxide dismutase","stat, signal transducers and activators of transcription","smac, second mitochondrial activator of caspases","tgf, tumour growth factor","timp, tissue inhibitor of metalloproteinases","tlr4, toll-like receptor 4","tnf, tumour necrosis factor","tslp, thymic stromal lymphopoietin","th17, t helper 17","treg, regulatory t","vcam-1, vascular cell adhesion molecule 1","vdac2, voltage-dependent anion channel 2","vegf, vascular endothelial growth factor","xiap, x-linked inhibitor of apoptosis protein","ykl-40, chitinase-like glycoprotein","ym2, chitinase 3-like protein 4","[ca2+]i, intracellular calcium ion","artemisinin","cell proliferation","eos, eosinophil","hsp47, heat shock protein 47","inos, inducible nitric oxide synthase","inflammation","lung","mtor, mammalian target of rapamycin","neu, neutrophil","shrna, short hairpin rna","sm-alpha, actin smooth muscle-alpha actin","u-pa, urokinase-type plasminogen activator"],"e_drugs":["artemisinine","Reactive Oxygen Species","Peroxides","Artemisinins"],"topics":["Treatment"],"weight":1,"_version_":1666802845647634432,"score":190.12769},{"pmid":32467086,"title":"Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.","text":["Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.","Clin Immunol","Omarjee, Loukman","Janin, Anne","Perrot, Frederique","Laviolle, Bruno","Meilhac, Olivier","Mahe, Guillaume","32467086"],"journal":"Clin Immunol","authors":["Omarjee, Loukman","Janin, Anne","Perrot, Frederique","Laviolle, Bruno","Meilhac, Olivier","Mahe, Guillaume"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32467086","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.clim.2020.108464","e_drugs":["Sirolimus"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668167109985697792,"score":133.43375},{"pmid":32425991,"pmcid":"PMC7233236","title":"The liver in times of COVID-19: What hepatologists should know.","text":["The liver in times of COVID-19: What hepatologists should know.","The ongoing pandemic of coronavirus disease 2019 (COVID-19) pandemic poses a serious threat to healthcare systems globally. Information regarding to the how the infection affects the liver and relevance of pre-existing liver disease as a risk factor for acquiring the infection or having a severe disease are still scarce. Also, considerations to be considered in liver transplant patients or those having hepatocellular carcinoma or are under immunosuppressive therapy are being matter of analysis as information is being generated. Different treatments for COVID-19 are currently under study some of which may be associated to hepatotoxicity. In the present review we discuss current data on the COVID-19 and liver aiming to provide hepatologists with updated information to face this pandemic.","Ann Hepatol","Ridruejo, Ezequiel","Soza, Alejandro","32425991"],"abstract":["The ongoing pandemic of coronavirus disease 2019 (COVID-19) pandemic poses a serious threat to healthcare systems globally. Information regarding to the how the infection affects the liver and relevance of pre-existing liver disease as a risk factor for acquiring the infection or having a severe disease are still scarce. Also, considerations to be considered in liver transplant patients or those having hepatocellular carcinoma or are under immunosuppressive therapy are being matter of analysis as information is being generated. Different treatments for COVID-19 are currently under study some of which may be associated to hepatotoxicity. In the present review we discuss current data on the COVID-19 and liver aiming to provide hepatologists with updated information to face this pandemic."],"journal":"Ann Hepatol","authors":["Ridruejo, Ezequiel","Soza, Alejandro"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425991","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.aohep.2020.05.001","keywords":["ace2, angiotensin-converting enzyme 2","alt, alanine aminotransferase","ards, acute respiratory distress syndrome","ast, aspartate aminotransferase","cdc, centers for disease control and prevention","covid-19, coronavirus disease 2019","evd, ebola virus disease","hbv, hepatitis b virus","hcc, hepatocellular carcinoma","icu, intensive care unit","il, interleukin","ilca, international liver cancer association","mafld, metabolic associated fatty liver diseases","nafld, non-alcoholic fatty liver disease","niddk, national institute of diabetes and digestive and kidney diseases","rdrp, rna-dependent rna polymerase","sars-cov-2","sars-cov-2, severe acute respiratory syndrome coronavirus 2","tnf-alpha, tumor necrosis factor-alpha","who, world health organization","coronavirus","immunosuppression","liver disease","nsp, non-structural proteins","transplantation, cirrhosis"],"topics":["Treatment"],"weight":1,"_version_":1667352728923275264,"score":82.83515},{"pmid":32292915,"pmcid":"PMC7142699","title":"The Imperfect Cytokine Storm: Severe COVID-19 with ARDS in Patient on Durable LVAD Support.","text":["The Imperfect Cytokine Storm: Severe COVID-19 with ARDS in Patient on Durable LVAD Support.","As health systems worldwide grapple with the COVID-19 pandemic, patients on durable LVAD support represent a unique population at risk for the disease. We outline such a patient who developed COVID-19 complicated by \"cytokine storm\" with severe ARDS and myocardial injury; and describe the challenges that arose during management.","JACC Case Rep","Chau, Vinh Q","Oliveros, Estefania","Mahmood, Kiran","Singhvi, Aditi","Lala, Anuradha","Moss, Noah","Gidwani, Umesh","Mancini, Donna M","Pinney, Sean P","Parikh, Aditya","32292915"],"abstract":["As health systems worldwide grapple with the COVID-19 pandemic, patients on durable LVAD support represent a unique population at risk for the disease. We outline such a patient who developed COVID-19 complicated by \"cytokine storm\" with severe ARDS and myocardial injury; and describe the challenges that arose during management."],"journal":"JACC Case Rep","authors":["Chau, Vinh Q","Oliveros, Estefania","Mahmood, Kiran","Singhvi, Aditi","Lala, Anuradha","Moss, Noah","Gidwani, Umesh","Mancini, Donna M","Pinney, Sean P","Parikh, Aditya"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292915","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaccas.2020.04.001","keywords":["ards","ards, acute respiratory distress syndrome","covid-19","lvad","lvad, left ventricular assist device","mods, multiorgan dysfunction syndrome","ovid-19, coronavirus disease 2019","pea, pulseless electrical activity","pi event, pulsatility index event","rv, right ventricle","sars-cov-2, severe acute respiratory syndrome coronavirus 2","cytokine storm"],"topics":["Case Report"],"weight":1,"_version_":1666138494463901696,"score":63.42082},{"pmid":32334502,"title":"The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment","text":["The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment","Multiple viral pathogens can pose a significant health risk to individuals. As a recent example, the beta-coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical to address this global concern. One such avenue that may prove to be exceedingly fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, mitochondrial dysfunction, and the onset of hyperinflammation, a significant disability associated with COVID-19. Furthermore, pathways that can activate mTOR may be necessary for anti-hepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with a greater understanding of this novel pathway, new treatments against several viral pathogens may successfully emerge.","Curr Neurovasc Res","Maiese, Kenneth","32334502"],"abstract":["Multiple viral pathogens can pose a significant health risk to individuals. As a recent example, the beta-coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical to address this global concern. One such avenue that may prove to be exceedingly fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, mitochondrial dysfunction, and the onset of hyperinflammation, a significant disability associated with COVID-19. Furthermore, pathways that can activate mTOR may be necessary for anti-hepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with a greater understanding of this novel pathway, new treatments against several viral pathogens may successfully emerge."],"journal":"Curr Neurovasc Res","authors":["Maiese, Kenneth"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32334502","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.2174/1567202617666200425205122","keywords":["amp activated protein kinase (ampk)","akt","covid-19","sars-cov-2","angiotensin converting enzyme 2","apoptosis","autophagy","coronaviruses","cytokines","diabetes mellitus","inflammation","influenza","interferons","interleukins","mtor complex 1 (mtorc1)","mtor complex 2 (mtorc2)","macrophage inflammatory protein 1-alpha (mip-1alpha)","mechanistic target of rapamycin (mtor)","metformin","monocyte chemoattractant protein 1 (mcp-1)","oxidative stress","tumor necrosis factor-alpha","virion"],"locations":["Rapamycin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494085365762,"score":60.171555}]}